PureTech Health spinout Celea Therapeutics will apply the financing toward a Phase 3 test of its idiopathic pulmonary (IPF) drug, deupirfenidone. The pivotal study will test the oral small molecule head-to-head against a standard of care IPF drug.
The post Lung-Focused Celea Secures $180M for Pivotal Test of Pulmonary Fibrosis Drug appeared first on MedCity News.
T3MP3ST Security Framework Turns AI Coding Agents Into 0-Day Bug Hunters
A newly released open-source security framework called T3MP3ST is turning general-purpose AI coding agents like Claude Code, OpenAI’s Codex, and Hermes into autonomous red-teaming operators
